Doctor discusses Ivermectin success in India, questions Canada’s COVID approach
03/12/2021 No Comments
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
No matter where you stand on how to best handle pandemic policy, Dr. Da Costa’s experience and view is worth a listen.
I’ve railed against this in the media that we are a part of, and the way that the propaganda reacts to this is, “Ignore it. Ignore all of this.” I’m saying this now because the general public has to be the one that gets angry. The general public should be furious at the way people have been treated in the country by suppression of these drugs, by that kind of website that suppresses the ability of doctors to practice medicine.
Source: FLCCC Alliance Community Author: Joyce Kamen Since January, 2020, Dr. Paul Marik, a tenured professor of medicine, has worked non-stop to try to understand
They also restricted the use of essential off-label and generic drugs with blatant disinformation campaigns that reminded Kory of big tobacco’s efforts to hide the dangers of smoking. In effect, the public health authorities eliminated the full toolbox of essential scientific methods and drugs that doctors use every day, including the most effective early, prophylactic, and late-stage treatments for COVID-19, which were developed by frontline doctors, not pharmaceutical companies.
In the professor’s continual review of “the latest (and best) literature,” he picked up a surprising “data signal” in October from emerging studies in Latin America. ivermectin, a safe, cheap, FDA-approved anti-parasitic drug, was showing remarkable anti-viral and anti-inflammatory activity as a repurposed drug—the most powerful COVID-19 killer known to science.
is perspective, highlights of the event, which attracted nearly 1,000 delegates, making it the largest C19 conference ever in the world.
In ‘Real Life’ this 10-day Ivermectin Triple Therapy reported here, appears to be a very safe, effective and inexpensive early antiviral treatment for Covid-19. Further detail from the more than 30 doctors involved in treating this patient group, will be used for a formal peer-reviewed publication.
The Attorney General provided a detailed, lengthy analysis to the Nebraska HHS lead, declaring that based on the available data, they “do not find clear and convincing evidence that a physician who first obtains informed consent and then utilizes ivermectin or hydroxychloroquine after COVID-19 violates UCA.”
In this interview, Dr. Peter McCullough discusses the importance of early treatment for COVID-19, and the potential motivations behind the suppression of safe and effective treatments.
We should group all the PrEP, PEP, and early treatment studies of HCQ together at the point at which we see temporal and dose dependent effects time and again. Such research should certainly be separated out, but at the point at which signs of antiviral action emerge so consistently, that observation ties the body of evidence together.
Researchers at the MUSC are now conducting clinical trials to help fight against COVID-19, but to settle questions surrounding the drug Ivermectin.
In this tweet, Dr. Robert Malone links here to a page on the globalcovidsummit.org website (in honor of the COVID-19 Summit in Rome) noting that over 3,900 physicians and medical scientists (passed 4,200 now) have signed the Rome Declaration in protest. The declaration was initially passed through the circles of those who attended Rome and gathered in San Juan, but is now open to all physicians and medical scientists. If that includes you, please read it and consider signing.
Pulmonary and critical care specialist Dr. Pierre Kory, author of the medical textbook Point of Care Ultrasound, is an educator and self-described pioneer in teaching doctors how to use ultrasound machines. In response to global health organizations’ seemingly one-note strategy in the fight against Covid, Kory states that other tactics need to be applied, particularly in light of the numerous breakthrough infections.
A board-certified family medical physician who works with Dr. George Fareed in California’s Imperial Valley, Dr. Brian Tyson states that, based on his work with more than 6,000 Covid patients, 70% of all cases nationwide could have been saved using his early-treatment methods.
ICU admission was significantly lower in the ivermectin group compared to controls among participants ≥40 year-old (1.2% vs 2.0, odds ratio 0.608; p=0.024).
Similarly, mortality was lower in the ivermectin group in the full group analysis (1.5% vs 2.1%, odds ratio 0.720; p=0.029), as well as in subjects ≥ 40 year- old (2.7% vs 4.1%, odds ratio 0,655; p=0.005).
In San Juan, Puerto Rico, a panel of doctors and scientists convened in an open forum about effective early treatment and evaluated the current one-size-fits-all approach to the treatment of Covid.
The May 2021 issue of Antibiotics Review, for example, put out a metanalysis of ivermectin which showed that 100% of 36 prophylaxis and early treatment studies showed positive results, and 26 of the studies showed “statistically significant improvements.”
The DEPUTY SPEAKER: I don’t think there is room for debate about the issues that the member for Hughes is raising. He’s entitled to put his point of view. He’s as relevant as I suspect he is going to be. I’d like him to continue.
In El Salvador, the Ministry of Public Health has embraced Ivermectin as part of a combination of recommendations for early treatment of COVID-19
We are pleased to present a webinar about a crucial topic: the early treatment of those catching COVID-19, especially with the Delta variant.
We are pleased to present a webinar about a crucial topic: the early treatment of those catching COVID-19, especially with the Delta variant. The Delta, which represents the vast majority of new cases in the US and many other countries, requires indeed a slightly different approach for its early treatment.
Dr Stramezzi talks about his experience, his perspectives on treatment of Covid-19, his telemedicine service & the upcoming International Covid Summit in Rome in September.
An in-depth interview with Dr. Tess Lawrie of EBMC Squared describing the effectiveness of long-time safe medicine ivermectin to treat and prevent covid and how health authorities are systematically ignoring the evidence.
This is a far reaching interview with Nick Hudson, who is the leader of PANDA, which stands for Pandemics Data & Analytics
This interview with Steve Kirsch features early treatment, vaccination, government responses to pandemics, tech companies & freedom of expression.
Two doses (300 μg/kg/dose in a gap of 72 hours) of ivermectin chemoprophylaxis reduced COVID-19 infection by 83% among HCWs for one month. Ivermectin is a safe and effective strategy to prevent COVID-19, in the containment of pandemic alongside vaccine. Further research is required to guide the frequency of chemoprevention, acceptability, and cost-effectiveness in the community setting.
Dr George Fareed provides an update about the outpatient treatment of COVID-19, for newly infected and for long covid patients.
This interview features Dr Caxton Opere, who has not only treated C19 patients but also written 3 books about it, the first one in early April 2020.
Altogether, this study brings the proof of concept that an IVM-based immunomodulatory therapy improves the clinical condition of SARS-CoV-2-infected hamsters, and in clinical trials, it alleviates symptoms of COVID-19 in humans and possibly limits post-COVID-19 syndrome (also known as long COVID) via an anti-inflammatory action.
The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.
We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.
The Roman/Hernandez meta-analysis comes at a politically contentious moment. Their language and behavior appear political. Their work is error-laden, takes research out of its true context, uses numbers that don’t seem to come from the actual studies, chooses papers testing ivermectin under the least favorable circumstances, gives unexplained and inappropriate weights to the small amount of data that stands as outliers to the bigger picture, and still drives a conclusion of “don’t use this” from a massive average mortality reduction that did not quite reach statistical significance. At the same time the authors consistently complain about the “low quality of evidence” represented by the studies they do and do not include, nearly all of which I would describe as produced by higher quality scientists who can at least tally numbers correctly.
Those who design the trials and control the data also control the outcome. So this system of industry-led trials needs to be put to an end.
Dr. Risch gives a succinct history of the politics of hydroxychloroquine and other useful existing medicines in the USA, which has had global effect, as many countries look to the USA for guidance. Corruption and manipulation from behind the scenes around the world are brought to the surface for scrutiny.
Source: Rounding The Earth Author: Mathew Crawford Since sometime last summer, I’ve paid (increasing) attention to much of the rapidly growing body of evidence that ivermectin (IVM)
Large reductions in Covid-19 deaths are possible using ivermectin.
Using ivermectin early may reduce the numbers progressing to severe disease.
Ivermectin is low cost.
The results not only provide a structural basis for the anti-SARS-CoV-2 activity of HCQ, but also renders HCQ to be the first known drug capable of targeting LLPS.
The authors concluded based on this extensive review that ivermectin actually reduced the risk of death compared with no ivermectin (average risk ratio 0.38, 95% CI 0.19-0.73; n = 2438; I2 = 49%; moderate-certainty evidence).
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
The SOLIDARITY and RECOVERY protocols look prima facie like staged sabotage.I drew a picture to make the point: The WHO could not have plausibly chosen a less optimal treatment protocol.